Key Takeaways
- • Amperos Health raised $16 million in Series A funding led by Bessemer Venture Partners, achieving a 3.8x capital increase within 10 months of its $4.2 million seed round in June 2025, signaling strong investor confidence in the AI-native denial-management category.
- • The company targets healthcare's $260 billion annual denial-management market, a structurally persistent operational inefficiency driven by denial volume growth outpacing human billing capacity.
- • Amperos demonstrates material traction: currently serving 3,000+ clinical locations across all 50 states and recovering nearly $700 million in revenue annually across 500,000+ claims, validating product-market fit at scale.
- • The platform differentiates as the industry's first AI-native denial-management solution, contrasting with incumbent RCM (revenue cycle management) vendors retrofitting large language models into legacy systems; the hybrid model pairs agentic AI automation with human subject-matter experts for complex appeals.
- • Founding team combines healthcare and AI expertise: CEO Michal Miernowski (ex-Onex, Goldman Sachs), CPO Alvin Wu (ex-Samsara, Fitbit), and CTO Wilson Wang; Series A round included participation from Uncork Capital and Neo alongside Bessemer.
Summary
Amperos Health, a New York City-based healthtech startup founded in 2023, has secured $16 million in Series A funding led by Bessemer Venture Partners, with follow-on participation from existing seed investors Uncork Capital and Neo. The financing round represents aggressive capital acceleration, occurring approximately 10 months after the company's $4.2 million seed round in June 2025, which itself featured participation from notable angel investors including OpenAI, Twilio, and Stripe.
The company operates in the denial-management and revenue-recovery segment of healthcare billing, a market characterized by structural inefficiency. Approximately $260 billion annually remains trapped in denied insurance claims across U.S. healthcare providers, a figure cited in Bessemer's investment thesis. The denial problem persists despite decades of incumbent solutions because denial volume has grown faster than the supply of qualified human billing professionals, creating operational bottlenecks in provider revenue cycle management.
Amperos positions itself as the industry's first AI-native denial-management platform, a strategic differentiation from the retrofit-LLM approach adopted by established RCM vendors. The company's technology pairs agentic AI systems—which automate end-to-end appeal and collections workflows—with a human team of subject-matter experts who handle complex or outlier cases requiring judgment. This hybrid model aims to recover higher proportions of denied claims while maintaining clinical accuracy and compliance standards.
The company demonstrates measurable early-stage traction. Amperos currently serves 3,000+ clinical locations across all 50 states and has recovered nearly $700 million in revenue annually across 500,000+ claims processed. This deployment breadth and recovery volume validate product adoption among providers and suggest the platform can operate at meaningful scale within the fragmented U.S. healthcare system.
The founding team combines relevant expertise across healthcare operations and technology. CEO Michal Miernowski brings experience from Onex and Goldman Sachs; CPO Alvin Wu previously worked at Samsara and Fitbit; CTO Wilson Wang completes the technical leadership. The Series A round positions the company to expand its clinical location footprint, deepen AI capabilities, and capture a larger share of the persistent $260 billion annual denial-management opportunity.
The company operates in the denial-management and revenue-recovery segment of healthcare billing, a market characterized by structural inefficiency. Approximately $260 billion annually remains trapped in denied insurance claims across U.S. healthcare providers, a figure cited in Bessemer's investment thesis. The denial problem persists despite decades of incumbent solutions because denial volume has grown faster than the supply of qualified human billing professionals, creating operational bottlenecks in provider revenue cycle management.
Amperos positions itself as the industry's first AI-native denial-management platform, a strategic differentiation from the retrofit-LLM approach adopted by established RCM vendors. The company's technology pairs agentic AI systems—which automate end-to-end appeal and collections workflows—with a human team of subject-matter experts who handle complex or outlier cases requiring judgment. This hybrid model aims to recover higher proportions of denied claims while maintaining clinical accuracy and compliance standards.
The company demonstrates measurable early-stage traction. Amperos currently serves 3,000+ clinical locations across all 50 states and has recovered nearly $700 million in revenue annually across 500,000+ claims processed. This deployment breadth and recovery volume validate product adoption among providers and suggest the platform can operate at meaningful scale within the fragmented U.S. healthcare system.
The founding team combines relevant expertise across healthcare operations and technology. CEO Michal Miernowski brings experience from Onex and Goldman Sachs; CPO Alvin Wu previously worked at Samsara and Fitbit; CTO Wilson Wang completes the technical leadership. The Series A round positions the company to expand its clinical location footprint, deepen AI capabilities, and capture a larger share of the persistent $260 billion annual denial-management opportunity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.